The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedImportance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian settingTyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functionsLong-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trResponse to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study.Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous LeukemiaTargeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experienceThe achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).The choice of first-line chronic myelogenous leukemia treatment.Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?Milestones and monitoring.Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.Re-emergence of interferon-α in the treatment of chronic myeloid leukemiaEarly responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesAssessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapyEvolution of definitions of response, progression-free survival and event-free survival in front-line studies of chronic myeloid leukemia.Treatment options for chronic myeloid leukemia.Chronic myeloid leukemia: state of the art in 2012.Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis.Treatments for chronic myeloid leukemia: a qualitative systematic review.Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.Management of the new patient with CML in chronic phase.Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.Response-related predictors of survival in CML.Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.
P2860
Q26738514-A0B7C9A2-4D30-40D4-B88B-2D7E87245BECQ27008389-31B105C7-9825-4181-98D2-8C1E7F1132B5Q28078946-D6984E4D-9A7A-409B-B70E-67C8AEBA36E6Q31033077-71EF99BF-D213-4A31-B963-413956A462A0Q33416063-17D2F8AE-D5E7-4DCD-AA9B-36919DD4383BQ33747792-1D1708F8-8C75-4E61-92E4-5CED847548E4Q33806617-04BF967B-7847-46BD-ACF9-4878F088819BQ33903030-CF77DFEA-EB5E-4F67-B9B9-AE955E68F625Q34022125-9B71E3FA-FA43-44EA-B1A0-B871832CB65FQ34163101-4651DDD1-C8C2-42FB-8CA2-A69556FCD65CQ34272962-7B8D5E96-CC2C-4D36-B153-75420D5F3533Q34310190-90CA3D27-7C87-4AA3-951A-C83B179E77CDQ35221071-8D171C94-3EDA-4B7C-8DD0-F38E28F4677BQ35565658-59F6786A-C54C-4238-A180-F854E98E40A0Q35652844-3C6214D2-D2DA-4656-A3C1-A7AC6D706D99Q36104098-9A565B85-C1F9-4162-A069-99D224ED4432Q36734508-F24CD878-B83E-4C4A-AA51-D275EEB58062Q36804884-42A830CB-A593-45B2-90FA-5B5B399D78D9Q36989407-65420325-DD9B-4FB9-9D94-12191E7FAA3BQ37095355-B23B7CE0-B964-40B3-927B-B68ADFE62E89Q37273161-B04B349E-2399-4E95-B2E0-08AAAD3F79DCQ37579983-4E7D1C63-9E72-4B22-A7EF-6ECF4BD20DE7Q37618894-77D52C1B-3AC9-4C6B-95FF-5C2FBE9EC341Q37973402-0F62C67C-2D9C-45BF-B721-91F2D8146D82Q37994805-7EE419A4-F88D-443B-A7FF-D0055566A123Q38028374-B5966C20-3AEB-4A02-8170-9E6F5B916F91Q38033115-593B1011-92D4-41BB-A94F-8EFC3032BC99Q38037079-5D09C407-9087-45A2-A354-1302CC508F7DQ38057413-F15E90BE-071F-458A-97AC-1ED720B120BDQ38079151-1FC24FBF-FF83-413D-BAC1-7E934C04EA7DQ38139571-C5705738-0223-4F87-8EA0-887C4D8FC28BQ38392705-71C444BE-CB99-4757-B9E3-16E9CB107DAAQ38404422-14310E34-0E91-423C-AEC4-B3CBEFE9B37CQ38585916-35F2D261-AEFA-4F2F-B040-622BE5DEB87EQ38598820-1EDBD80C-4442-49DC-AEBF-CC22E4BD5D22Q38685803-49EFA262-0C9C-4D91-9078-72729BA0F834Q38802249-24DAB300-2A3F-431C-A57D-1C3653629B0FQ39285841-48FADB4D-95DF-4F3F-8E0F-991D57B23B40Q39350678-01414822-53FB-4F8F-80E6-E728DE8018D6Q39457369-DEDDE1AC-3260-4DE1-A3F2-22D1E8A2EE4C
P2860
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The achievement of an early co ...... ith tyrosine kinase inhibitors
@ast
The achievement of an early co ...... ith tyrosine kinase inhibitors
@en
type
label
The achievement of an early co ...... ith tyrosine kinase inhibitors
@ast
The achievement of an early co ...... ith tyrosine kinase inhibitors
@en
prefLabel
The achievement of an early co ...... ith tyrosine kinase inhibitors
@ast
The achievement of an early co ...... ith tyrosine kinase inhibitors
@en
P2860
P50
P921
P1433
P1476
The achievement of an early co ...... ith tyrosine kinase inhibitors
@en
P2093
Jenny Shan
P2860
P304
4541-6; quiz 4759
P356
10.1182/BLOOD-2011-04-348110
P407
P50
P577
2011-07-29T00:00:00Z